English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A ‘vascular normalization index’ (VNI) based on the changes in the magnetic resonance imaging (MRI) parameters K trans  and cerebral blood volume (CBV), combined with blood sampling, has been shown to correlate with patient outcome in recurrent glioblastoma after a single dose of antiangiogenic therapy. Here, by applying a novel contrast agent extravasation correction method insensitive to variations in tissue mean transit time, we show that a similar VNI parameter can be derived from a single dynamic susceptibility contrast MR acquisition rather than the three parameters shown previously. Our results show that this new VNI parameter, which combines changes in tumoral CBV and an apparent transfer constant from our leakage correction method, may provide prognostic information in an even simpler manner than prior efforts.

journal of cerebral blood flow and metabolism

T<sub>1</sub>- and T<sub>2</sub>*-Dominant Extravasation Correction in DSC-MRI: Part II—Predicting Patient Outcome after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

T1- and T2*-Dominant Extravasation Correction in DSC-MRI: Part II—Predicting Patient Outcome after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

T₁- and T₂*-Dominant Extravasation Correction in DSC-MRI: Part II—Predicting Patient Outcome after a Single Dose of Cediranib in Recurrent Glioblastoma Patients